Low-Risk and Very-Low-Risk Prostate Cancer: Is There a Role for Focal Therapy in the Era of Active Surveillance? Yes, the Two Approaches Complement Each Other
The challenge in prostate cancer (PCa) is to match the aggressiveness of the treatment to that of the cancer. Until recently, all screen-diagnosed localized cancers were considered at least potentially aggressive and in most cases were treated radically. Active surveillance represented a major step forward in acknowledging that some cancers were clinically insignificant and did not pose a threat to the patient’s life. Recently, a third option—focal therapy—has emerged as a potential middle ground between radical treatment and active surveillance. Read the article.